Avixgen Signs $360 Million Licensing Deal with US Biotech Firm for Next-Gen Drug Delivery Platform

Subordinate of Dx&Vx Avixgen Entered a Licensing-out Agreement with a US Biotech Company 

Announcement

Avixgen, a secondary of Dx&Vx, declared on 18th August 2025 that it has entered a licensing out agreement at USD 360 million with a US biotechnology company to introduce a next-generation drug delivery platform for advanced cell penetrating peptides (ACPP). Avixgen is a known drug development company in which Dx&Vx has a 66.2% stake. According to a licensing-out agreement, Avixgen offered the partner company, a us biotechnology company, a limited proprietary license of ACP patents, and the partner will develop and initiate them for its drug development representatives. The US biotechnology company will pay Avixgen around USD 360 million in development and upfront profit payments. Including royalties for 10 years after marketization becomes individual. Additional details of the agreement will be out upon request from the partner company.

Avixgen’s ACP Platform

The ACP platform, solely discovered by Avixgen, is a peptide-related drug delivery technology introduced with a different structure. The platform provides balanced and efficient delivery of drugs into cells and tissues by a simple mixing technique or conjugation with numerous drugs. With vast accessibility across peptides, nucleic acids, and small molecules, like even antibodies and RNA, it is examined as a next-generation technology with increased scalability. In a few preclinical animal studies, ACP progressively penetrated the blood-brain barrier (BBB), called is a popular hurdle in drug delivery, showing safe results and ACP-conjugated drugs that enhance motor function in ill animals.

This is analyzed as showcasing a practical solution to the phenomenon of CNS (central nervous system) focused therapeutics, which is hard to achieve along with the existing drug delivery technologies. Avixgen and Dx&Vx are companies with technological potency and expertise, one of the South Korean biotech companies in advancing peptide-related drug delivery technologies, and have accrued delivery technologies and therapeutics accordingly on various peptide platforms. The agreement shared a limited portion of ACP’s remarkable scalability. The BBB patents are not a part of the contract. Anyway, the deal of USD 360 million in profit and upfront payments marks an empowering result.

Views and Statements from the Company Leaders

CEO of Avixgen, Sung Jun Han, said, “This agreement is the first ever agreement for our company and reflects a fruition of years of consistent research and development efforts. We are thankful to our partner for addressing the value of our technology, and we hope to leverage global market entry and further partnership extension with this contract as a successful move.”